Prostate cancer is known to have a tissue tropism for bone. This tissue tropism coupled with the experience with androgen deprivation therapy (ADT) over the past decade has led to heightened awareness of bone complications. Osteopenia and subsequent skeletal-related events (SREs) are one of the more concerning repercussions of ADT along with cardiovascular sequelae. To combat this decrease in bone mineral density, several agents have been developed for bone protection. The largest experience is with bisphosphonates (BPs), but recently (2011) head to head trials have established the role of monoclonal antibodies, particularly in patients with prostate cancer bone metastasis. For patients initiating ADT, monthly denosumab increased bone mineral density, the time for occurrence of any bone metastasis and time for symptomatic bone metastasis. Denosumab is a fully human monoclonal antibody of the IgG 2 subtype that selectively binds and neutralizes receptor activator NF kappa B ligand (RANKL), inhibiting osteoclastogenesis and bone turnover. In vitro binding assays have shown high-affinity binding of denosumab and osteoprotegerin to both soluble and membrane-bound forms of human RANKL. As clinicians may be less familiar with this newer agent, we compiled this review to summarize denosumab's current clinical indications for bone stabilization and mechanism of reduction in tumor burden. (2012) 
MECHANISM OF ACTION
Bone turnover is controlled by a cytokine pathway that belongs to the tumor necrosis factor family responsible for osteoclastic bone resorption. 1 --6 This system consists of a molecular triad of receptor activator NF kappa B ligand (RANKL), its receptor (RANK), and decoy receptor osteoprotegerin (OPG). RANKL is a membranebound protein, critical for the formation, function and survival of osteoclasts, that is expressed on the surface of myeloid osteoclasts precursors. 7, 8 RANKL binds to its receptor, RANK, on the surface of osteoclast precursor cells initiating osteoclastogenesis and activating mature osteoclasts in the presence of macrophage colonystimulating factor-1. OPG is a protein and soluble member of the tumor necrosis factor receptor superfamily produced by osteoblasts and stromal cells that acts a decoy receptor, competing with RANK for RANKL. When bound to RANKL, OPG inhibits the interaction between RANKL and RANK, which in turn inhibits osteoclastogenesis. 9 See Figure 1 . Osteoclastogenesis is frequently observed in bone metastasis as a result of increased RANKL and/or decreased OPG secretion. 10 Animal models of bone metastases have demonstrated the therapeutic role of RANKL inhibitors (that is, RANK-Fc or OPG-Fc) to inhibit osteolytic bone resorption associated with cancer-induced skeletal-related events (SREs). 11, 12 Denosumab (Amgen, Thousand Oaks, CA, USA) is a fully human monoclonal antibody of the IgG 2 subtype that selectively binds and neutralizes RANKL, inhibiting osteoclastogenesis and bone turnover. The mechanism by which denosumab prevents the interaction between RANKL and RANK is analogous to the native OPG-RANK interaction. In vitro binding assays have shown high-affinity binding of denosumab and OPG to both soluble and membrane-bound forms of human RANKL. 5 Denosumab does not neutralize murine or rodent RANKL, so it has not been studied in typical animal models of bone metastasis. It has, however, been studied extensively in several double-blind randomized clinical trials comparing denosumab to zoledronic acid (ZA) in patients with bone metastases from solid tumors as well as in patients with nonmetastatic prostate and breast cancer. 3,13 --17 Although there is clearly strong evidence for bone stabilization and improved quality of life, the direct anti-tumor effects at either primary or metastatic sites may be inferred but has not been proven. In this review, we have differentiated a reduction in tumor burden from bone stabilization.
CURRENT CLINICAL INDICATIONS
Denosumab was approved in November 2010 by the US Food and Drug Administration (FDA) for the prevention of SREs in patients with bone metastases from solid tumors based on superior results in three phase III clinical trials that compared denosumab with ZA. 3, 13, 14 It was not approved for use in multiple myeloma because the difference did not reach statistical significance. 14 In September 2011, the FDA approved denosumab for use in patients with nonmetastatic prostate cancer on androgen deprivation therapy (ADT). As this is a disparate patient population, denosumab is marketed as Prolia for this indication. 4 Although current indications support its use in renal cell carcinoma metastasis or transitional cell bone metastasis, the foremost use for urologists will likely be in prostate cancer populations.
PRECLINICAL EVIDENCE OF POTENTIAL ANTICANCER ACTIVITY
Emerging preclinical evidence suggests that RANKL inhibition may have an important role in the prevention and treatment of bone metastasis. 18, 19 Because denosumab does not neutralize murine or rodent RANKL, it has not been studied directly in any animal models of bone metastasis. Instead, the murine analogs of denosumab, murine RANK-Fc and OPG-Fc have been studied extensively in preclinical breast cancer, melanoma, and prostate cancer models (Table 1 ). The reduction in tumor burden by denosumab may be through its direct inhibition of RANKL, or indirectly through its downstream effects on gene expression.
EXPRESSION OF RANKL/RANK/OPG IN CANCER
Preclinical studies have demonstrated that expression of RANKL, RANK and OPG is altered in primary and metastatic human prostate cancer cells. 18 The expression of RANK mRNA has been detected in human prostate cancer cell lines, including androgeninsensitive DU145, C42B and PC3, as well as androgen-sensitive LNCap. 20 In an analysis of the surgical biopsy specimens of 89 patients with prostate cancer, 48 of which had primary disease, RANKL, RANK and OPG expression were quantified using immunohistochemical analysis. In this study, RANKL, RANK, and OPG were positive in 31, 38 and 19% of specimens, respectively, in patients with primary disease. 20 A greater proportion of specimens were positive in patients with metastatic disease 44%, 49% and 73%, respectively, with the highest levels of production of RANKL, RANK and OPG observed at the invasive front of prostate cancer cells compared with the central portion. 20 Researchers found that expression of RANKL, RANK and OPG correlated with tumor stage, grade, Gleason score, androgen receptor status and PSA with the highest levels of expression in advanced metastatic tumors, supporting the hypothesis that the RANKL/RANK/OPG triad is involved in prostate cancer metastasis. 20 OPG expression has been of special interest to researchers owing to its therapeutic potential because of its inhibitory effect on RANKL. Several studies have demonstrated that serum OPG increases in patients with bone metastases when compared with patients with non-osseous metastases and primary tumors. 21 --24 One possible explanation is that increases in OPG may be a compensatory response to bone remodeling or secondary to increased tumor burden. This would explain in part denosumab's ability to thwart bone metastasis, because its activity mimics that of native OPG, which inhibits osteoclastogenesis.
BONE STABILIZATION (TUMOR MICROENVIRONMENT)
Denosumab directly and specifically inhibits RANKL, causing a decrease in the number of tumor-associated osteoclasts. 25 A study by Canon et al. 26 modeled bone metastasis using MDA-MB-231 human breast cancer cells in mice to evaluate the effect of RANKL inhibition on skeletal tumor progression. Bones containing breast cancer cells exhibited significantly increased RANKL protein levels, and serum OPG levels were significantly elevated in mice with established lytic bone lesions compared with tumor-free control mice. 26 In this study, RANKL inhibition by recombinant OPG (OPGFc) caused a dose-dependent decrease in the number of tumorassociated osteoclasts, with the group that received 3.0 mg kg --1 of OPG-Fc twice weekly exhibiting complete inhibition of osteoclastogenesis after 18 days of treatment. 26 OPG-Fc treatment also had a dose-dependent effect on survival, with the 3 mg kg --1 OPG-Fc treatment group (over the 0.3 mg kg --1 dose) demonstrating a 20% increase in survival time over control mice. 26 Together, these results support the hypothesis that tumor growth affecting the 27 Bone lesion progression and tumor growth was evaluated using plain radiographs, hindlimb tumor size, 18F-Fluorodeoxyglucose and 18F-fluoride micro PET-CT, histology and histomorphometry. 27 Mean tumor sizes were significantly lower in the retronoggin and retrognoggin with RANK-Fc groups (108.6 and 108 mm 3 ) compared with the control group (159.5 mm 3 ). Further, the animals treated with both retronoggin and RANK-Fc exhibited delayed development of bone lesions, inhibition of osteolysis, and preservation of bone architecture with less tumor-induced new bone formation. 27 This study provided compelling evidence that RANK-Fc indirectly limits tumor growth and tumor-mediated osteolysis, but that it does not directly inhibit tumor growth.
TUMOR BURDEN (ANTICANCER)
One of the proposed mechanisms of the anticancer activity of denosumab includes its ability to act directly on RANK-expressing tumor cells, including breast, prostate and melanoma cancer cell lines. 20,19,28 --30 RANKL may serve as a chemo-attractant factor for migration of PC3 human prostate cancer cells to bone, a hypothesis tested by treating PC3 cells with RANKL. 18 In vitro studies demonstrated increased invasion of PC3 cells through a collagen matrix, an effect abrogated by the addition of OPG-Fc, supporting the hypothesis that RANK activation by RANKL is ample to cause invasion. 18 Jones et al. 19 further characterized the role of in vivo inhibition of RANKL with OPG-Fc. Injection of B15F10 melanin-producing melanoma cells into syngeniec C57B/L6 mice resulted in rapid metastasis of cancer cells to long bones, vertebrae, ovaries and choroid plexus. 19 Subsequent treatment with OPG-Fc reduced melanoma cancer foci and tumor burden in all bones at all time points analyzed, but in contrast, showed no difference in tumor burden and metastasis in the ovaries, adrenals and brain compared with controls, highlighting the specificity of OPG for bone metastasis. Notably, none of the animals treated with OPG-Fc developed clinical spinal cord paralysis by the end of the experiment, day 17, compared with nearly 90% of controls. 19 Treatment with ZA, which also suppresses osteoclast activation, did not reduce tumor metastasis to bone, 19 suggesting RANKL may be acting directly on tumor cells.
In addition to its direct role in initiating osteoclastogenesis, RANKL activity may also include modulation of gene expression. To test this hypothesis, Armstrong et al.
18 measured systemic levels of RANKL and OPG in mice inoculated with PC3 human prostate cancer cells known to cause osteolytic lesions. Results included a six-fold increase in RANKL in PC3 tumor-bearing mice versus naïve mice, and a two-fold increase in OPG levels. In this study, treatment of PC3 cells with RANKL resulted in rapid stimulation of MAP kinase p38 and ERK phosphorylation inducing signaling events downstream, changing the expression of 42 different genes. Using ELISA, researchers confirmed the upregulation of cytokines implicated in stimulation of osteoclasts and osteolysis in disease states, including CSF-1, IL-1b, tumor necrosis factor-a, IL-8 and IL-6. 19, 31 Despite the increased production of cytokines, RANKL has not been shown to alter PC3 cell proliferation in vitro or affect the sensitivity of PC3 cells to a variety of chemotherapeutics, including, CPT-11, doxorubicin, 5-fluorouracil, etoposide or cisplatin. 19 In addition to upregulation of genes involved in chemotaxis, migration and invasion of cancer cells, preclinical studies have also investigated the role of the RANKL/RANK/OPG system in altering the cell cycle. In vitro studies have shown that RANKL-dependent hyperplasia correlates with elevated levels of cyclin D1, a protein specific to the G1/S phase of the cell cycle. 32, 33 In a spontaneous mammary tumor model in MMTV-neu mice, RANKL inhibition with murine RANK-Fc reduced proliferation and cyclin D1 selectively within normal mammary epithelia, but not within adenocarcinomas. 33 These data imply that the action of denosumab on the cell cycle is to protect against premalignant changes. In vivo treatment of late-stage tumors with RANKL resulted in fewer apoptotic cells, prolonging the survival of tumor cells. 34 To evaluate the effect of OPG-Fc on tumor cell survival, MDA-231 Luc tumor cells in bone were analyzed for caspase-3, a marker of cell apoptosis. 26 The tumors cells in bone-treated with 3.0 mg kg --1 OPG-Fc twice weekly demonstrated significantly higher rates of apoptosis compared with control treatment. 26 Miller et al. 35 evaluated the therapeutic use of OPG-Fc compared with docetaxel, an antimitotic agent that prevents microtubule depolymerization. Male athymic nu/nu mice were challenged with PC3 prostate cancer cells, and then treated with docetaxel, OPG-Fc, or a combination treatment with both agents. At day 27, mice treated with docetaxel showed 80.8% reduction in hind limb tumor growth compared with a 20.9% reduction in the OPG-Fc treatment group as measured by bioluminescence. The authors attributed this apparent discrepancy to the analytic approach of bioluminescence. When they used direct histological analysis of the skeletal tumor burden, they found that OPG-Fc and docetaxel reduced histologic tumor burden within the bone by 82% and 83%, respectively. 35 Combination of the treatments enhanced the antitumor effect to 97.5% reduction compared with the control group, upon histological analysis. Median survival time with either OPG-Fc or docetaxel monotherapy did not differ significantly, although the distribution of their effects did. Docetaxel was able to reduce both intrabone and extramedullary tumor growth because its effects were independent of tumor localization, whereas OPG-Fc effects are limited to skeletal sites. 26, 35 ROLE IN METASTASIS In a study of the effect of direct RANK ligand inhibition in mice with carcinogen-induced mammary tumors, RANK-Fc initiated concurrently with carcinogen administration almost completely inhibited growth of palpable mammary tumors in wild-type mice, an effect not observed with the bisphosphonate (BP) ZA. 33 Moreover, this study also found that RANK-Fc treatment initiated at 5 months in MMTV-neu mice had no significant impact on median time to spontaneous mammary tumor onset, but that it did significantly reduce the total number of mammary tumors quantified at necropsy. Additionally, treatment with RANK-Fc reduced the incidence and number of lung metastases per mouse. 33 A study by Tan et al. 34 produced similar results using a mammary carcinoma cell line, MT2, in MMTV-Erbb2 mice. Pulmonary metastasis was observed in 100% of mice inoculated with MT2 cells, however, after silencing RANK expression pulmonary metastasis was only observed in 50% of mice, and the number of metastases per mouse was also significantly reduced. 34 These two studies provide evidence that inhibition of the RANK/RANKL interaction may decrease the frequency of tumor metastasis, but whether this prolongs survival remains an area for further study.
EARLY CLINICAL TRIALS
Early clinical data from a phase 1 clinical trial of patients diagnosed with breast cancer (n ¼ 29) or multiple myeloma (n ¼ 25) and radiologically confirmed bone lesions showed that denosumab is non-inferior to the BP, pamidronate. 15 In this study, patients received a single subcutaneous dose of either denosumab (0.1, 0.3, 1.0, or 3.0 mg kg   --1 ) or intravenous pamidronate (90 mg). Bone resorption was quantified by measuring urinary and serum N-telopeptide (NTX) levels, serum bone-specific alkaline phosphatase, and serum albumin-adjusted calcium periodically for 84 days at regularly scheduled visits. Results included a significant reduction in median urinary NTX as early as 1 day after the first dose of denosumab or pamidronate. Suppression of urinary NTX was dose-dependent in the denosumab cohorts. The decrease in magnitude of bone marker turnover was more sustained using the intermediate and high doses of denosumab, whereas the effect of intravenous pamidronate progressively diminished through the study. Decreases in median bone-specific alkaline phosphatase were modest, as expected, because alkaline phosphatase is found on the surface of osteoblasts, whereas denosumab was specifically developed to target osteoclasts. Although studies involving bone turnover markers are proof of principle, their relevance to clinical practice may be questioned. Hence, translational studies were needed to link surrogates for bone complications such as NTX with clinical endpoints.
CLINICAL TRIALS
One of the first such translational studies was a randomized, openlabel phase 2 clinical trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, multiple myeloma and other solid tumors that compared its anticancer activity with that of intravenous BPs. 16 In this study, 111 patients were randomized to continue intravenous BPs every 4 weeks (ZA or pamidronate) or to receive subcutaneous injections of denosumab 180 mg every 4 weeks (Q4W) or denosumab 180 mg every 12 weeks (Q12W) for 25 weeks. The primary end point was urinary NTX o50 nmol l --1 bone collagen equivalents/mM creatinine, which at week 13 was observed in 49 (71%) of 69 patients in the denosumab arms compared with 10 (29%) of 35 patients in the intravenous BP arm (Po0.001). At week 25, the proportion of patients with urinary NTX lower than 50 was 64% in the denosumab arm versus 37% in the intravenous BP arm (P ¼ 0.01). An important clinical observation in this study was first on-study SREs (fracture, surgery or radiation to bone, or spinal cord compression) during the 25-week treatment period, which was observed in 8% (six of 73) for the denosumab arms versus 17% (six of 35) for the intravenous BP arm (OR, 0.31; 95% CI, 0.08 to 1.18) . 15 Authors of this study also observed a 2.5-fold greater suppression of TRAP-5b, an osteoclast biomarker, in patients in the denosumab arm. 16 Similar findings using urinary NTX as the primary endpoint were demonstrated in a phase 2, randomized controlled study of denosumab as compared with ZA in patients with breast cancer-related bone metastasis. 17 These studies demonstrated the ability of denosumab to further suppress bone resorption in patients already receiving intravenous BPs, proving that denosumab works through a different or additional mechanism than BPs.
In a recent phase 3 randomized, double-blind clinical study of denosumab versus ZA in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma by Henry et al., SREs were used as the primary endpoint.
14 In this study, 1776 patients were randomized to 120 mg subcutaneous denosumab (n ¼ 886) or 4 mg intravenous ZA (dose adjusted for renal impairment; n ¼ 890). An SRE was defined as a pathologic fracture, radiation or surgery to bone, or spinal cord compression. Results showed that denosumab was non-inferior to ZA in delaying time to first on-study SREs (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P ¼ 0.0007).
14 Although denosumab showed a trend towards superiority, it was not statistically superior to ZA in delaying time to first on-study SREs or time to first-and subsequent (multiple) SREs. Similarly, overall survival and disease progression were comparable between the two treatments groups. Additional information gleaned from this study included the side-effect profile of denosumab compared with ZA. Hypocalcemia occurred more frequently with denosumab (10.8% denosumab; 5.8% ZA), however, the clinical consequences of hypocalcemia were not observed. Osteonecrosis of the jaw, a known side effect of ZA, occurred at similar rates in the denosumab and ZA groups, 1.1% and 1.3% at 3 years, respectively. Lastly, overall renal adverse events were slightly more common in patients treated with ZA compared with denosumab, 10.9% and 8.3%, respectively. Role of denosumab in prostate cancer S Helo et al Role of denosumab in prostate cancer S Helo et al
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